English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17918/22933 (78%)
Visitors : 7437829      Online Users : 108
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    CSMUIR > Medical College > Institute of Medicine > Journal paper >  Item 310902500/21573
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/21573


    Title: MicroRNA‑10b modulates cisplatin tolerance by targeting p53 directly in lung cancer cells
    Authors: Lin, Chen-Chu
    Liao, Wan-Ting
    Yang, Tsung-Ying
    Lu, Hsueh-Ju
    Hsu, Shih-Lan
    Wu, Chun-Chi
    Contributors: 中山醫學大學;醫研所
    Keywords: p53;miR-10b;lung cancer;drug tolerance;prognosis
    Date: 2021-06-22
    Issue Date: 2021-08-11T02:20:08Z (UTC)
    Publisher: Spandidos Publications
    ISSN: 1791-2431
    Abstract: MicroRNA (miRNA or miR)‑10b is an oncogenic miRNA associated with metastasis that is present in various types of tumor, including lung cancer. However, whether miR‑10b is involved in different malignant characteristics, such as drug resistance or stemness, remains unclear. Therefore, the present study investigated whether miR‑10b is an upstream regulator of p53. Ectopic expression of miR‑10b‑agomir decreased the expression of p53 and its downstream effectors, such as Bax and p53 upregulated modulator of apoptosis. Two non‑canonical sites, including 1,580‑1,587 and 2,029‑2,035, located in p53 3'‑untranslated region (UTR) were affected by the presence of miR‑10b. In functional assays, upregulation of the p53 signaling pathway following cisplatin treatment was associated with decreased levels of miR‑10b and upregulation of the luciferase activity of wild‑type, but not 1,584, 2,032‑dual‑mutant, p53 3'‑UTR. The ectopic expression of miR‑10b‑agomir attenuated the stability of p53 3'‑UTR and the expression of p53 and its downstream effectors induced by cisplatin. By contrast, the knockdown of miR‑10b induced the stability of p53 3'‑UTR and increased levels of p53 and the sensitivity of A549 cells to cisplatin treatment. Similar results were also observed for Beas 2B cells. In the clinical investigation, p53 exhibited two distinct associations (cocurrent and countercurrent) with miR‑10b in patients with lung cancer. Patients with lung cancer with low p53 and high miR‑10b levels exhibited the poorest prognosis, while those with high p53 and low miR‑10b exhibited the most favorable prognosis. These findings indicate a novel pathway in which cisplatin induces the levels of p53 by increasing mRNA stability via miR‑10b, indicating a novel oncogenic role of miR‑10b in promoting the malignant characteristics of non‑small cell lung carcinoma.
    URI: https://ir.csmu.edu.tw:8080/handle/310902500/21573
    Relation: Oncology Reports, Volume 46, Issue 2
    Appears in Collections:[Institute of Medicine] Journal paper

    Files in This Item:

    There are no files associated with this item.



    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback